Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 11Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 5Triple Negative Breast Neoplasms 4Neoplasms 4Sarcoma 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Lymphoma 2Liver Neoplasms 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Recurrence 1Prostatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Metastatic Pancreatic Ductal Adenocarcinoma 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1

Interventions

Fluorouracil 34Cisplatin 34Radiotherapy 30Oxaliplatin 30Paclitaxel 22pembrolizumab 20Irinotecan 20Docetaxel 20Leucovorin 19Capecitabine 16Cetuximab 11Carboplatin 11Bevacizumab 11Radiation 10Surgical Procedures, Operative 9Trastuzumab 8Panitumumab 6Epirubicin 6Neoadjuvant Therapy 5Esophagectomy 4Erlotinib Hydrochloride 4Chemotherapy, Adjuvant 4tisotumab vedotin 3durvalumab 3Sunitinib 3Microarray Analysis 3Immunohistochemistry 3Gene Expression Profiling 3Gemcitabine 3Albumin-Bound Paclitaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Esophageal Neoplasms × spartalizumab × Clear all
NCT04171141 2025-01-16

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

Pfizer

Phase 1 Terminated
79 enrolled 42 charts
Gastrointestinal

Digestive System Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡